Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 73

Cited In for PubMed (Select 12837834)

1.

Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.

Tomioka A, Tanaka N, Yoshikawa M, Miyake M, Anai S, Chihara Y, Okajima E, Hirayama A, Hirao Y, Fujimoto K.

BMC Cancer. 2015 May 20;15(1):420. doi: 10.1186/s12885-015-1429-0.

2.

A phase II RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy.

Alibhai SM, Santa Mina D, Ritvo P, Sabiston C, Krahn M, Tomlinson G, Matthew A, Segal R, Warde P, Durbano S, O'Neill M, Culos-Reed N.

BMC Cancer. 2015 Apr 25;15(1):312. doi: 10.1186/s12885-015-1316-8.

3.

Primary androgen deprivation therapy for prostate cancer in koreans: a retrospective multicenter study.

Seo WI, Kang PM, Kim TH, Moon KH, Chung JM, Lee DH, Kim IY, Min K, Chung J, Kim W, Kang DI.

World J Mens Health. 2014 Dec;32(3):159-66. doi: 10.5534/wjmh.2014.32.3.159. Epub 2014 Dec 29.

4.

Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?

Eom KY, Ha SW, Lee E, Kwak C, Lee SE.

Radiat Oncol J. 2014 Dec;32(4):247-55. doi: 10.3857/roj.2014.32.4.247. Epub 2014 Dec 30.

5.

Feasibility of robot-assisted radical prostatectomy for very-high risk prostate cancer: surgical and oncological outcomes in men aged ‚Č•70 years.

Koo KC, Jung DC, Lee SH, Choi YD, Chung BH, Hong SJ, Rha KH.

Prostate Int. 2014 Sep;2(3):127-32. doi: 10.12954/PI.14050. Epub 2014 May 21.

6.

Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.

Krahn MD, Bremner KE, Luo J, Alibhai SM.

Curr Oncol. 2014 Jun;21(3):e457-65. doi: 10.3747/co.21.1865.

7.

Utility of FDG-PET in clinical neuroendocrine prostate cancer.

Spratt DE, Gavane S, Tarlinton L, Fareedy SB, Doran MG, Zelefsky MJ, Osborne JR.

Prostate. 2014 Aug;74(11):1153-9. doi: 10.1002/pros.22831. Epub 2014 Jun 9.

PMID:
24913988
8.

Quality of Life and Sexual Health in the Aging of PCa Survivors.

Gacci M, Baldi E, Tamburrino L, Detti B, Livi L, De Nunzio C, Tubaro A, Gravas S, Carini M, Serni S.

Int J Endocrinol. 2014;2014:470592. doi: 10.1155/2014/470592. Epub 2014 Mar 17. Review. Erratum in: Int J Endocrinol. 2015;2015:675101.

9.

Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.

Potosky AL, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Jiang M, Tsai HT, Luta G, Keating NL, Smith MR, Van Den Eeden SK.

J Clin Oncol. 2014 May 1;32(13):1324-30. doi: 10.1200/JCO.2013.52.5782. Epub 2014 Mar 17.

10.

The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer.

Lawrenson R, Obertov√° Z, Brown C, Fong P, Tyrie L, Scott N, Holmes M.

J Cancer. 2014 Feb 14;5(3):214-20. doi: 10.7150/jca.8152. eCollection 2014.

11.

Management of patients with biochemical recurrence after local therapy for prostate cancer.

Paller CJ, Antonarakis ES, Eisenberger MA, Carducci MA.

Hematol Oncol Clin North Am. 2013 Dec;27(6):1205-19, viii. doi: 10.1016/j.hoc.2013.08.005. Epub 2013 Sep 18. Review.

12.

Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality.

Etzioni R, Durand-Zaleski I, Lansdorp-Vogelaar I.

J Natl Cancer Inst Monogr. 2013;2013(46):117-23. doi: 10.1093/jncimonographs/lgt010.

13.

Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer.

Keating NL, Liu PH, O'Malley AJ, Freedland SJ, Smith MR.

Eur Urol. 2014 Apr;65(4):816-24. doi: 10.1016/j.eururo.2013.02.023. Epub 2013 Feb 22.

14.

Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.

Cooperberg MR, Ramakrishna NR, Duff SB, Hughes KE, Sadownik S, Smith JA, Tewari AK.

BJU Int. 2013 Mar;111(3):437-50. doi: 10.1111/j.1464-410X.2012.11597.x. Epub 2012 Dec 28.

15.

Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening.

Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM.

Med Care. 2013 Apr;51(4):295-300. doi: 10.1097/MLR.0b013e31827da979.

16.

Denosumab: a new option in the treatment of bone metastases from urological cancers.

Yuasa T, Yamamoto S, Urakami S, Fukui I, Yonese J.

Onco Targets Ther. 2012;5:221-9. doi: 10.2147/OTT.S30578. Epub 2012 Sep 21.

17.

Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy.

Greenspan SL, Wagner J, Nelson JB, Perera S, Britton C, Resnick NM.

J Bone Miner Res. 2013 Feb;28(2):325-32. doi: 10.1002/jbmr.1771.

18.
19.

Management of biochemical recurrence after primary localized therapy for prostate cancer.

Darwish OM, Raj GV.

Front Oncol. 2012 May 23;2:48. doi: 10.3389/fonc.2012.00048. eCollection 2012.

20.

The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines.

Etzioni R, Gulati R, Tsodikov A, Wever EM, Penson DF, Heijnsdijk EA, Katcher J, Draisma G, Feuer EJ, de Koning HJ, Mariotto AB.

Cancer. 2012 Dec 1;118(23):5955-63. doi: 10.1002/cncr.27594. Epub 2012 May 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk